Four Ways to Test Your Mitochondria: What Each One Actually Measures

Edited by Samael A. Tejada, Founder & Editor-in-Chief

Why do four “mitochondria tests” give you four different kinds of answer?

Because they are not measuring the same thing. A useful way to line them up is as a ladder of directness — how close the measurement sits to your own mitochondria actually doing their job:

1. Enzyme activity in your own cells — Mitome and MitoSwab. A lab measures how fast specific respiratory-chain enzymes from your cheek cells can process their substrates. That is real biochemistry on your own tissue. But it is a maximum-capacity reading on broken-up cells: no oxygen consumption, no ATP production rate, no living system under load.
2. A living-cell response to your blood — ME Screen. Your serum is applied to a standard line of laboratory cells, and those cells' respiration and stress responses are measured. The readout is dynamic and physiological, but the mitochondria in it are not yours.
3. Metabolite leftovers — Metabolomix+. A urine panel reads organic acids — including the Krebs-cycle intermediates your mitochondria consume and produce — plus nutrient and oxidative-stress markers. It describes the supply lines feeding your mitochondria, not the mitochondria themselves.

None of the four measures the thing people imagine when they say “mitochondrial function”: your own cells breathing and making ATP in real time. Keep that gap in mind as you read each section.

What does Mitome actually measure?

Mitome (mito.me) is the newest name in this group, launched direct-to-consumer in December 2025 by Chris Masterjohn, PhD, a nutritional-sciences researcher. You order online — no physician is involved — swab the inside of each cheek twice at home (four swabs total), freeze the samples, and ship them back by FedEx on a weekday. The price is $699, one-off, with free shipping.

The lab work is spectrophotometric enzyme assay on your cheek cells — the same classic technique used in mitochondrial-disease work-ups. Five measurements come back:

• Complex I, Complex II, Complex II+III (a combined segment assay spanning Complex II, the coenzyme Q pool, and Complex III — not a standalone Complex III reading), and Complex IV activity
• Citrate synthase activity, a marker of how much mitochondrial material the cells contain, used to normalize the other values

Each result is reported as a percentage of a control-group mean, labeled Low, Low-Normal, Normal, or High (the company defines Normal as 70–140% of the control mean). Your values are then classified into one or more of 12 proprietary “patterns,” and a patent-pending algorithm — designed by Masterjohn and described by the company as built on peer-reviewed literature plus in-house cross-referencing of past clients' results — converts them into a personalized food, supplement, and lifestyle protocol of roughly 15–30 pages.

What Mitome does well is scope: it is the widest enzyme panel you can buy as a consumer, and the deliverable is an action plan, not just numbers. What it does not measure is just as important. There is no Complex V, no oxygen-consumption or respiration measurement, no ATP production rate, and no DNA or metabolite testing in the core kit. And one warning about a word you may see in coverage of this test: a single third-party article describes a proprietary “MitoScore.” That term appears nowhere in Mitome's own sample report, which contains no composite score and no mitochondrial-age number. Treat “MitoScore” as unverified.

Practical wrinkles worth knowing before you buy: the company's own pages disagree about turnaround (3–5 weeks on one page, 4–6 weeks from lab receipt in its FAQ), a spoiled sample costs a $50 replacement fee, and the report itself states that its content “has not been reviewed or approved by the FDA” and is “not intended for clinical or diagnostic use.”

Evidence label: Preliminary for the underlying assay method (see the validation section); Absent for Mitome's own pattern algorithm and protocol, for which no published validation could be found.

What does MitoSwab actually measure?

MitoSwab (ReligenDX) is the established version of the same idea — and the comparison piece this article extends covers it in depth. The short version: two cheek swabs, collected at home, and the lab measures Complex I and Complex IV activity plus citrate synthase in your own cheek cells, reported against published control ranges. A physician must order it, results go to that physician, and the price on the lab's own requisition form is $350. It runs in a CLIA-certified laboratory as a laboratory-developed test; it is not FDA-cleared or approved.

Its strengths are real: it measures your own enzymes, its method and control ranges are published, and it is the only test in this group with a validation study against muscle biopsy (below). Its limits are also real: a narrower panel than Mitome's, cheek cells rather than muscle or brain, enzyme capacity in an extract rather than respiration in a living cell, and repeat measurements that vary by roughly 13–16% between runs — so small changes are within noise. You must also stop mitochondria-related supplements at least seven days before swabbing, and the sample is temperature-sensitive.

Evidence label: Preliminary — one developer-run validation study, with independent expert opinion notably cooler than the marketing.

What does ME Screen actually measure?

ME Screen (Verséa Discovery) takes a different route entirely. You prick a finger at home and put a few drops of blood on a card that separates and dries the serum. Anyone can buy it online for $699 — no prescription — and results arrive two to three weeks after the lab receives the sample.

The lab then rehydrates your serum and applies it to a proprietary line of living laboratory cells. It measures those cells: their oxygen consumption, the reactive oxygen species they produce under stress, how their mitochondrial networks hold together — grouped into Energy Profile, Mito ROS, Mito Network, and Energy Balance scores and combined into a single composite the company calls the mescore.

The technology is genuinely sophisticated. The problem is whose mitochondria it describes: the cell line's, not yours. What is yours is the serum — the hormones, inflammatory signals, metabolites, nutrients, and medications circulating in your blood that day — and anything from an infection to a hard workout to a poor night's sleep can move that milieu without your mitochondria changing at all. The company does not publish the mescore's scale, weighting, normative database, or test-retest reliability, and no peer-reviewed study validating the commercial test could be found. It is sold for research and informational use and states it has not been reviewed by the FDA.

Evidence label: Absent — for the commercial test itself, published validation could not be found.

What does Metabolomix+ actually measure?

Metabolomix+ (Genova Diagnostics) is the outlier: it does not claim to measure your mitochondria, and it doesn't. It is a broad nutritional and metabolic panel run on a first-morning urine sample (optional blood-spot and cheek-swab add-ons cover other markers), reporting 125+ biomarkers: organic acids, amino acids, oxidative-stress markers, vitamin markers, and toxin and detoxification markers. One section — “Cellular Energy and Mitochondrial Metabolites” — reports Krebs-cycle intermediates such as citrate, alpha-ketoglutarate, succinate, fumarate, malate, lactate, and pyruvate: the fuels and exhaust of the energy pathway your mitochondria run.

That makes Metabolomix+ a supply-side test. Where the enzyme assays ask “how fast can the machines run?”, this panel asks “what is being delivered to the machines, and what is backing up?” Abnormal patterns in these metabolites can point a clinician toward nutrient-cofactor shortages or metabolic bottlenecks worth investigating. What the panel cannot do is grade your mitochondria: a urine lactate or citrate level reflects whole-body metabolism, kidney handling, diet, and gut microbes as well as mitochondrial activity, and no study validates this panel as a measure of mitochondrial function.

Access and price: Genova's tests are ordered through a licensed healthcare provider (its own consumer channel adds a physician fee), and the panel lists around $425–$475 before add-ons, depending on channel. Genova is a long-established CLIA-certified laboratory, and urine organic-acid analysis is a conventional, decades-old clinical chemistry method — the measurements are standard laboratory work. It is the leap from metabolite pattern to “mitochondrial health” conclusions that is interpretive.

Evidence label: Established as an analytical method (routine clinical organic-acid testing, published analytes); Absent as a validated grade of mitochondrial function — that is not what the panel is validated for.

Side by side: Mitome vs. MitoSwab vs. ME Screen vs. Metabolomix+

Are Mitome and MitoSwab the same test underneath?

This is the question a careful buyer eventually asks, because the resemblance is strong — and there is documentary evidence worth seeing, presented here for exactly what it is.

Mitome never names its laboratory partner; its site says only that data is “generated by our lab partner.” But Mitome's own collection instructions tell customers to enclose “the completed MITOSWAB lab order form” with their swabs. And Mitome's own company timeline states: “2017 — Mitoswab makes buccal respiratory chain tests commercially available. 2025 — Mitome launches its comprehensive analysis of dietary and supplemental implications of respiratory chain activity.” By Mitome's own telling, then, its contribution is the interpretation layer — the patterns and the protocol — built on a buccal respiratory-chain assay that has existed commercially since 2017. MitoSwab is the ReligenDX buccal-swab platform.

We want to be precise about the strength of that evidence. The order-form wording and the timeline come from Mitome's own documents, and the panel matches (respiratory-chain complexes plus citrate synthase, from cheek swabs, by spectrophotometry). That makes “Mitome's lab work runs on the MitoSwab platform” a strong inference. It is not a confirmed fact: Mitome has not publicly named ReligenDX as its lab, and no document we found says the two companies have a contract. If the inference is right, one practical consequence follows — the differences between a $350 MitoSwab and a $699 Mitome would be the wider enzyme panel, the direct-to-consumer access (no physician gate), and the interpretive protocol, not a different underlying measurement.

How strong is the validation behind each test?

The buccal enzyme assay (Mitome's and MitoSwab's shared foundation): one real study, with real limits. Goldenthal and colleagues (Molecular Genetics and Metabolism, 2012; PMID 22189081) compared cheek-swab enzyme results with muscle biopsy in 40 patients already known to have Complex I or Complex IV defects, against 106 unaffected controls. The swab reproduced the muscle defect in just over 82% of cases — and the correlation held only for Complex I and Complex IV, the two complexes actually studied. Nothing in that paper validates Complex II or II+III readings, pattern classification, or testing in healthy wellness consumers; the cohort was suspected-disease patients, largely children. Later expert reviews have been cooler still, describing buccal enzyme testing's sensitivity and specificity for mitochondrial disease as poor. Mitome's own sample report concedes its reference ranges rest on control data lacking “large sample sizes and associated statistical precision,” and Mitome does not disclose the size or makeup of its control population.

Mitome's algorithm: no published validation. No peer-reviewed study of the 12-pattern classification, the protocol's recommendations, or any health outcome from following them could be found. The company describes the framework as its founder's own design, cross-referenced in-house against past clients' results.

ME Screen: no published validation of the commercial test. What exists is an unpublished company claim of compound-screening sensitivity, two small single-arm pilots that use the assay as a measuring stick, and — awkwardly for the premise — a large, pre-registered 2026 study (Ryback and colleagues, PLoS ONE) that applied patient and control sera to healthy muscle cells across 1,700+ stress tests and found no difference. That study did not test ME Screen itself, but it is the best independent evidence on serum-transfer testing as a class, and it is negative.

Metabolomix+: established chemistry, different claim. Urine organic-acid measurement is routine clinical laboratory work with published analytes and reference intervals, used for decades in metabolic medicine. What has not been validated — because it is not the panel's clinical claim — is any conversion of those metabolites into a grade of an individual's mitochondrial function.

And across all four: no published study shows that making decisions from any of these results improves any health outcome. That evidence is absent for the entire category, not just one brand.

Which test should you choose for which question?

• “A doctor suspects something is wrong with my mitochondria.” None of these is a diagnosis, and diagnosis today is led by genetic testing with a specialist. Of the four, only MitoSwab sits inside a physician-ordered, CLIA pathway with any biopsy comparison behind it — as an adjunct, ordered and interpreted by that doctor. ME Screen's maker states it is not for diagnosis; Mitome's report says the same about itself.
• “I want to know how my respiratory chain is performing, and I want a plan.” That is Mitome's exact pitch, and its panel is the widest on offer. Go in knowing the plan's algorithm is unvalidated in print, the control ranges are imprecise by the company's own admission, and the same underlying assay family is available for less through a physician.
• “I want a number to track over time.” Every option here is noisy. MitoSwab's between-run variability (~13–16%) at least tells you how big a change has to be before it means anything; ME Screen publishes no equivalent figure for the mescore, so its movements currently cannot be interpreted. Whoever you choose: standardize collection conditions, retest at most a few times a year, and ignore small moves.
• “I want to know if I'm missing the nutrients my mitochondria need.” That is a supply question, and it is the one Metabolomix+ is actually built to inform — read with a clinician who can separate a genuine cofactor gap from whole-body noise. It will not tell you how your mitochondria themselves are performing, and it should not be sold to you as if it does.

The bottom line: the word “mitochondria test” currently covers an enzyme assay on your own cells, a cell-culture experiment run on your serum, and a urine metabolite panel — at prices from $350 to $699, with validation ranging from one modest 2012 study to none at all. The tests that claim to grade your mitochondria should be graded just as hard.

Where the evidence stands

• Established: Urine organic-acid analysis (Metabolomix+) is standard clinical laboratory chemistry with published analytes; Mitome and MitoSwab both assay respiratory-chain enzyme activity in the customer's own cheek cells by spectrophotometry (method and control ranges published for the buccal assay, Goldenthal 2012, PMID 22189081).
• Preliminary: Cheek-swab enzyme results agree with muscle biopsy in known disease cases — just over 82% for Complex I and IV defects in 40 pre-selected patients vs. 106 controls (Goldenthal 2012); developer-run, largely pediatric, and covering only Complexes I and IV.
• Preliminary: Mitome's lab work runs on the MitoSwab platform. The evidence is Mitome's own collection sheet (“MITOSWAB lab order form”) and its own timeline crediting MitoSwab's 2017 commercial launch — a strong inference, not a confirmation; Mitome names no lab partner.
• Contested: Buccal enzyme testing is an accurate stand-alone screen for mitochondrial disease. Independent expert reviews describe poor sensitivity and specificity and no proven reflection of high-energy tissues (Muraresku/Falk 2018, PMID 30393588; Mitochondrial Medicine Society consensus).
• Contested: Serum-transfer testing reveals a person's mitochondrial state in laboratory cells. The method's predecessor studies are small and single-arm (Dzotsi 2025, PMID 41038948); the largest independent, pre-registered serum-transfer experiment found no patient-vs.-control difference (Ryback 2026, PMID 41632778).
• Absent: Mitome's 12-pattern algorithm and personalized protocol are validated. No peer-reviewed validation, no published outcomes, and no disclosed control population could be found; the company's own sample report concedes its ranges lack statistical precision.
• Absent: ME Screen's mescore is a validated measure of your mitochondrial function. No peer-reviewed validation of the commercial test, and no published scale, norms, or reproducibility, could be found.
• Absent: Metabolomix+ grades mitochondrial function. It is a nutritional/metabolic urine panel; no validation supports converting its metabolites into a mitochondrial function score.
• Absent: Any of the four tests improves health outcomes when used to guide supplements or lifestyle changes. No published study shows result-guided decisions improving any clinical outcome for any of them.